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18-MethoxycoronaridineThe interaction of 18-methoxycoronaridine (18-MC) with nicotinic acetylcholine receptors (AChRs) was
compared with that for ibogaine and phencyclidine (PCP). The results established that 18-MC: (a) is more
potent than ibogaine and PCP inhibiting (±)-epibatidine-induced AChR Ca2+ inﬂux. The potency of 18-MC is
increased after longer pre-incubation periods, which is in agreement with the enhancement of [3H]cytisine
binding to resting but activatable Torpedo AChRs, (b) binds to a single site in the Torpedo AChR with high
afﬁnity and inhibits [3H]TCP binding to desensitized AChRs in a steric fashion, suggesting the existence of
overlapping sites. This is supported by our docking results indicating that 18-MC interacts with a domain
located between the serine (position 6′) and valine (position 13′) rings, and (c) inhibits [3H]TCP, [3H]
ibogaine, and [3H]18-MC binding to desensitized AChRs with higher afﬁnity compared to resting AChRs. This
can be partially attributed to a slower dissociation rate from the desensitized AChR compared to that from
the resting AChR. The enthalpic contribution is more important than the entropic contribution when 18-MC
binds to the desensitized AChR compared to that for the resting AChR, and vice versa. Ibogaine analogs
inhibit the AChR by interacting with a luminal domain that is shared with PCP, and by inducing
desensitization.eutical Sciences, College of
e., Glendale, AZ 85308, USA.
.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Nicotinic acetylcholine receptors (AChRs) are members of the Cys-
loop ligand-gated ion channel superfamily that also includes types A
and C γ-aminobutyric acid (GABA), type 3 5-hydroxytryptamine
(serotonin), and glycine receptors (reviewed in [1–5]). The alkaloid
ibogaine and its natural and synthetic analogs behave pharmacolog-
ically as noncompetitive antagonists (NCAs) of several AChRs [6–8]. It
has been hypothesized that this inhibitory activity is related to their
anti-addictive properties [8–12]. In particular, 18-methoxycoronar-
idine (18-MC) has higher speciﬁcity for the α3β4 AChR [9]. This
receptor subtype is expressed in relatively high amounts in the
habenulo-interpeduncular pathway which modulates the mesocorti-
colimbic pathway, the so-called “brain reward circuitry” [8–11].
Considering this evidence, possible roles for AChRs in the process ofdrug addiction and consequently as targets for the pharmacological
action of anti-addictive drugs have been suggested [10].
A better understanding of the interaction of ibogaine analogs with
AChRs is crucial to develop novel compounds for safer anti-addictive
therapies. However, we do not have structural and functional
information on the interaction of 18-MC with its binding site(s)
when the AChR is in different conformational states, especially
considering that AChR desensitization seems to play an important
role in the process of drug addiction (reviewed in [13]). As a ﬁrst
attempt to study this interaction we chose the muscle-type AChR
because it is the archetype of the Cys-loop ligand-gated ion channel
superfamily and because we can manipulate the different receptor
conformational states in a variety of in vitro assays. We also used this
particular AChR type because the binding site locations of several
NCAs have already been characterized, including that for phencycli-
dine (PCP) [14–19] (reviewed in [3]). Taking advantage of this
previous knowledge, the mutual interaction between 18-MC and PCP
in the AChR is compared. To reﬁne our understanding of the
interaction between 18-MC and the AChR, we compared this
interaction with that for ibogaine, the archetype of this family of
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functional approaches including radioligand binding assays employ-
ing several NCAs {i.e., [3H]18-MC, [3H]ibogaine, and [3H]TCP, the
analog of PCP, [piperidyl-3, 4-3H(N)]-N-(1-(2 thienyl)cyclohexyl)-
3,4-piperidine} and the agonist [3H]cytisine, as well as Ca2+ inﬂux
assays, kinetics and thermodynamic measurements, and molecular
modeling and docking studies. Although this study does not intend to
determine the anti-addictive properties of ibogaine analogs, the
results from this work will pave the way for a better understanding of
how these compounds interact with the AChR.
2. Materials and methods
2.1. Materials
[Piperidyl-3, 4-3H(N)]-(N-(1-(2 thienyl)cyclohexyl)-3,4-piperi-
dine) ([3H]TCP; 45 Ci/mmol), and [3H]cytisine hydrochloride
(35.6 Ci/mmol) were obtained from PerkinElmer Life Sciences
Products, Inc. (Boston, MA, USA), and stored in ethanol at −20 °C.
[3H]18-Methoxycoronaridine ([3H]18-MC; 25 Ci/mmol) was pre-
pared by American Radiolabeled Chemicals Inc. (Saint Louis, MO,
USA) by tritium labeling of the 18-methoxycoronaridine hydrochlo-
ride salt synthesized as previously described [12]. [3H]Ibogaine
(23 Ci/mmol), ibogaine hydrochloride, and phencyclidine hydrochlo-
ride (PCP) were obtained through the National Institute on Drug
Abuse (NIDA) (NIH, Baltimore, USA). Carbamylcholine chloride (CCh),
suberyldicholine dichloride, pepstatin A, leupeptin, aprotinin, calpain
I, calpain II, benzamidine, cholesterol, phosphatidylserine, sphingo-
myelin, phosphatidic acid, phenylmethylsulfonyl ﬂuoride (PMSF),
polyethylenimine, sodium cholate, bovine serum albumin (BSA), and
(±)-epibatidine were purchased from Sigma Chemical Co. (St. Louis,
MO, USA). α-Bungarotoxin (α-BTx) was obtained from Invitrogen Co.
(Carlsbad, CA, USA). [1-(Dimethylamino) naphtalene-5-sulfonamido]
ethyltrimethylammonium perchlorate (dansyltrimethylamine) was
purchased from Pierce Chemical Co. (Rockford, IL, USA). Fetal bovine
serum and trypsin/EDTA were purchased from Gibco BRL (Paisley,
UK). Salts were of analytical grade.
2.2. Preparation of Torpedo AChR native membranes, cellular membrane
afﬁnity chromatography (CMAC) column, and chromatographic system
AChR native membranes were prepared from frozen Torpedo
californica electric organs obtained from Aquatic Research Consultants
(San Pedro, CA, USA) by differential and sucrose density gradient
centrifugation, as described previously [20]. Total AChR membrane
protein was determined by using the bicinchoninic acid protein assay
(Thermo Fisher Scientiﬁc, Rockford, IL, USA). Speciﬁc activities of
these membrane preparations were determined by the decrease in
dansyltrimethylamine (6.6 µM) ﬂuorescence produced by the titra-
tion of suberyldicholine into receptor suspensions (0.3 mg/mL) in the
presence of 100 µM PCP and ranged from 1.0 to 1.2 nmol of
suberyldicholine binding sites/mg total protein (0.5–0.6 nmol
AChR/mg protein). The AChR membrane preparations were stored
at −80 °C in 20% sucrose.
The CMAC-Torpedo AChR column was prepared by immobilization
of solubilized Torpedo AChR membranes following a previously
described protocol [21,22]. Torpedo AChR membranes (500 mg)
were ﬁrst homogenized in buffer A (50 mM Tris–HCl buffer, pH 7.4,
containing 1 mMpepstatin A, 20 µM leupeptin, 1 mM aprotinin, 1 mM
calpain I, 1 mM calpain II, 1 mM benzamidine, 2 mM MgCl2, 3 mM
CaCl2, 100 mM NaCl, 5 mM KCl, and 0.2 mM PMSF), and subsequently
solubilized in buffer A containing 2% (w/v) sodium cholate and 10%
(v/v) glycerol, in the presence of 100 nM cholesterol, 60 µM
phosphatidylserine, 20 µM sphingomyelin, and 60 µM phosphatidic
acid. Then, 200 mg of the Immobilized Artiﬁcial Monolayer (IAM)
liquid chromatographic stationary phase (ID=12 µM, 300 Å pore;Regis Chemical Co.) was suspended in the supernatant, and the
mixturewas rotated at room temperature (RT) for 1 h. The suspension
was dialyzed for 1 day against 1 L of 50 mM Tris–saline buffer, pH 7.4,
containing 5 mM EDTA, 100 mM NaCl, 0.1 mM CaCl2, and 0.1 mM
PMSF. The suspension was then centrifuged at 700 ×g at 4 °C and the
pellet (Torpedo-IAM) was washed three times with 10 mM ammoni-
um acetate buffer, pH 7.4. The stationary phase was packed into a HR
5/2 column (GE Healthcare, Piscataway, NJ, USA) to yield a
150 mM×5 mM (ID) chromatographic bed, the CMAC-Torpedo AChR
column.
Finally, the CMAC-Torpedo AChR column was attached to the
chromatographic system Series 1100 Liquid Chromatography/Mass
Selective Detector (Agilent Technologies, Palo Alto, CA, USA)
equipped with a vacuum de-gasser (G 1322 A), a binary pump
(1312 A), an autosampler (G1313 A) with a 20 µL injection loop, a
mass selective detector (G1946 B) supplied with atmospheric
pressure ionization electrospray and an on-line nitrogen generation
system (Whatman, Haverhill, MA, USA). The chromatographic system
was interfaced to a 250 MHz Kayak XA computer (Hewlett-Packard,
Palo Alto, CA, USA) running ChemStation software (Rev B.10.00,
Hewlett-Packard).
A 10 µL sample of 10 µM 18-MC was injected onto the CMAC-
Torpedo AChR column, and the alkaloid was monitored in the positive
ion mode using single ion monitoring at m/z=369.1 [MW+H]+ ion
with the capillary voltage at 3000 V, the nebulizer pressure at 35 psi,
and the drying gas ﬂow at 11 L/min at a temperature of 350 °C.2.3. Ca2+ inﬂux measurements in TE671 cells expressing human fetal
muscle AChRs
The TE671 cell line is a human rhabdomyosarcoma cell line
(obtained from American Type Culture Collection, USA) that endog-
enously expresses the human fetal muscle AChR (i.e., α1β1γδ). This
receptor subtype has the same subunit composition as the Torpedo
AChR and thus, comparative correlations can be assessed. TE671 cells
were cultured in a 1:1 mixture of Dulbecco's Modiﬁed Eagle Medium
(DMEM) and Ham's F-12 Nutrient Mixture (Seromed, Biochrom,
Berlin, Germany), supplemented with 10% (v/v) fetal bovine serum,
as previously described [22–24]. DMEM/Ham's F-12 contains 1.2 g/L
NaHCO3, 3.2 g/L sucrose, and stable glutamine (L-Alanyl-L-Glutamine,
524 mg/L). The cells were incubated at 37 °C, 5% CO2 and 95% relative
humidity. The cells were passaged every 3 days, by detaching the cells
from the culture ﬂask by washing with phosphate-buffered saline
and brief incubation (3–5 min) with trypsin (0.5 mg/mL)/EDTA
(0.2 mg/mL).
Ca2+ inﬂux was determined as previously described [22–24].
Brieﬂy, 5×104 TE671 cells per well were seeded 72 h prior to the
experiment on black 96-well plates (Costar, New York, USA) and
incubated at 37 °C in a humidiﬁed atmosphere (5% CO2/95% air). 16–
24 h before the experiment, the medium was changed to 1% BSA in
HEPES-buffered salt solution (HBSS) (130 mM NaCl, 5.4 mM KCl,
2 mM CaCl2, 0.8 mM MgSO4, 0.9 mM NaH2PO4, 25 mM glucose,
20 mM HEPES, pH 7.4). On the day of the experiment, the medium
was removed by ﬂicking the plates and replaced with 100 µL HBSS/1%
BSA containing 2 µM Fluo-4 (Molecular Probes, Eugene, Oregon, USA)
in the presence of 2.5 mM probenecid (Sigma, Buchs, Switzerland).
The cells were then incubated at 37 °C in a humidiﬁed atmosphere (5%
CO2/95% air) for 1 h. Plates were ﬂicked to remove excess of Fluo-4,
washed twice with HBSS/1% BSA, and ﬁnally reﬁlled with 100 µL of
HBSS containing different concentrations of the ligand under study,
and pre-incubated for 5 min, or for 4 and 24 h in the case of 18-MC. To
determine the inhibitory mechanism for 18-MC, additional experi-
ments were performed by pre-incubating the cells with 1, 10, and
100 µM 18-MC, respectively, before the (±)-epibatidine-induced Ca2+
inﬂux determinations.
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imaging plate reader (FLIPR) (Molecular Devices, Sunnyvale, CA, USA). A
baseline consisting of 5 measurements of 0.4 s each was recorded. (±)-
Epibatidine (1 µM)was then added from the agonist plate to the cell plate
using the FLIPR 96-tip pipettor simultaneously toﬂuorescence recordings
for a total length of 3 min. The laser excitation and emissionwavelengths
are 488 and 510 nm, at 1W, and a CCD camera opening of 0.4 s.
2.4. Equilibrium binding of [3H]18-MC to the Torpedo AChR
In order to determine the binding afﬁnity of [3H]18-MC for the
Torpedo AChR, equilibrium binding assays were performed as
previously described [15]. Brieﬂy, Torpedo AChR native membranes
(0.5 µM) were suspended in binding saline (BS) buffer (50 mM Tris–
HCl, 120 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4), in
the presence of 1 mM CCh (desensitized/CCh-bound state), and pre-
incubated for 30 min at RT. The [3H]18-MC equilibrium binding to the
resting AChR could not be determined because of a higher noise/
signal level. The total volume of themembrane suspensions (total and
nonspeciﬁc binding) was divided into aliquots and increasing
concentrations of [3H]18-MC+18-MC (i.e., 0.07 nM–1.2 µM) were
added to each tube and incubated for 2 h at RT. Nonspeciﬁc binding
was determined in the presence of 100 µM 18-MC. Speciﬁc binding
was calculated as total binding (no 18-MC)minus nonspeciﬁc binding
(in the presence of 18-MC). AChR-bound [3H]18-MC was then
separated from free radioligand by a ﬁltration assay using a 48-
sample harvester system with GF/B Whatman ﬁlters (Brandel Inc.,
Gaithersburg, MD, USA), previously soaked with 0.5% polyethyleni-
mine for 30 min. Themembrane-containing ﬁlters were transferred to
scintillation vials with 3 mL of Bio-Safe II (Research Product
International Corp, Mount Prospect, IL, USA), and the radioactivity
was determined using a Beckman 6500 scintillation counter (Beck-
man Coulter, Inc., Fullerton, CA, USA).
Using the Prism software (GraphPad Software, San Diego, CA,
USA), binding data were ﬁtted according to the Rosenthal–Scatchard
equation [25]:
B½ = F½  = − B½ = Kdð Þ + Bmax = Kdð Þ ð1Þ
where the dissociation constant (Kd) for [3H]18-MC is obtained from
the negative reciprocal of the slope. The stoichiometry of [3H]18-MC
binding sites in the membrane preparation can be estimated from the
x-intersect (when y=0) of the plot [B]/[F] versus [B], where the
obtained value corresponds to the number of [3H]18-MC binding sites
(Bmax) per the used concentration of total proteins (0.5 µM).
2.5. Radioligand binding experiments using Torpedo AChRs in different
conformational states
To determine the binding afﬁnity of ibogaine analogs for the Torpedo
AChR ionchannel, the inﬂuenceof 18-MCon [3H]TCPbinding, the effect of
PCP, ibogaine, and 18-MC on [3H]18-MC binding, and the effect of 18-MC
on [3H]ibogaine binding to Torpedo AChRs in different conformational
stateswas studied. In this regard, AChRnativemembranes (0.3 µM)were
suspended inBS bufferwith 7 nM [3H]TCP or 3.6 nM [3H]18-MCor 19 nM
[3H]ibogaine in the presence of 1 mM CCh (desensitized/CCh-bound
state), or with 15 nM [3H]TCP or 5.5 nM [3H]18-MC in the presence of
1 µM α-BTx (resting/α-BTx-bound state), and pre-incubated for 30 min
at RT. α-Bungarotoxin is a competitive antagonist that maintains the
AChR in the resting (closed) state [26]. Nonspeciﬁc binding was
determined in the presence of 50 µM PCP (for the [3H]TCP and [3H]
ibogaine experiments in the desensitized/CCh-bound state), 50 µM 18-
MC (for the [3H]18-MC experiments in the desensitized/CCh-bound
state), or of 100 µM PCP or 100 µM 18-MC (for the [3H]TCP and [3H]18-
MC experiments in the resting/α-BTx-bound state, respectively), as was
used previously [14–17,22,24].To determine whether 18-MC and ibogaine modulate agonist
binding to AChRs, Torpedo AChRmembranes (0.3 µM) were incubated
with 7.7 nM [3H]cytisine in the resting but activatable state (no other
ligand present) as described previously [24]. The nonspeciﬁc binding
was determined in the presence 1 mM CCh.
The total volume was divided into aliquots, and increasing
concentrations of the ligand under study were added to each tube
and incubated for 2 h at RT. AChR-bound radioligand was then
separated from free radioligand by using the ﬁltration assay described
in Section 2.4.
The concentration–response data were curve-ﬁtted by non-linear
least-squares analysis using the Prism software. The corresponding
IC50 values were calculated using the following equation:
θ = 1= 1 + L½ = IC50ð ÞnH
  ð2Þ
where θ is the fractional amount of the radioligand bound in the
presence of inhibitor at a concentration [L] compared to the amount of
the radioligand bound in the absence of inhibitor (total binding). IC50
is the inhibitor concentration at which θ=0.5 (50% bound), and nH is
the Hill coefﬁcient. The nH values were summarized in Table 2.
The observed IC50 values from the competition experiments
described above were transformed into inhibition constant (Ki) values
using the Cheng–Prusoff relationship [27]:
Ki = IC50 = 1 + ligand½ = K ligandd
 n o
ð3Þ
where [ligand] is the initial concentration of the used radioligand (i.e.,
[3H]TCP, [3H]18-MC, [3H]ibogaine), and Kdligand is the dissociation
constant for [3H]TCP in the resting (0.83 µM; [15]) and desensitized
(0.25 µM; [28]) states, [3H]ibogaine (5.4 µM; [29]), and [3H]18-MC in
the desensitized state (0.23 µM, see Fig. 2). The value for [3H]18-MC in
the resting state was taken from the [3H]TCP competition experiments
(1.4 µM, see Table 2). In addition, the free energy change (ΔG) for the
interaction of the NCAs with the receptor was determined using the
following equation (reviewed in [1]):
ΔG = RT lnKi ð4Þ
where R is the gas constant (8.3145 J mol−1 K−1), and T is the
experimental temperature in Kelvin (293 K). The calculated Ki and ΔG
values for the NCAs were summarized in Table 2.
2.6. Schild-type analysis for 18-MC-induced inhibition of [3H]TCP
binding
Tohave abetter indicationwhether 18-MC inhibits [3H]TCPbinding to
the desensitized AChR by a steric or allosteric mechanism, 18-MC-
induced inhibition of [3H]TCP binding experiments were performed at
increasing initial concentrations of unlabeled PCP (i.e., 0, 3.1, 6.3, and
9.4 µM, respectively). The rationale of this experiment is based on the
expectation that, for a higher initial concentration of the radioligand, a
higher concentration of the competitor will be necessary to produce a
total inhibition of radioligand binding. This is consistent with Schild-type
analysis [30]. From these competition curves the apparent IC50 values
were obtained from the plots according to Eq. (2). Then, we plot the ratio
between the IC50 values for 18-MC determined at different initial
concentrations of unlabeled PCP under the IC50 control values (no PCP
added) versus the initial PCP concentration (IC5018-MC/IC50control versus
[PCP]initial) (for more details see [14]). A linear relationship from this
modiﬁed Schild-type plot would indicate a competitive interaction,
whereas anon-linear relationshipwould suggest an allostericmechanism
of inhibition [14,30].
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chromatography
To determine the kinetic parameters for 18-MC, chromatographic
elutions of 18-MC from the CMAC-TorpedoAChR columnwere carried out
using amobile phase composed of 10 mMammonium acetate buffer (pH
7.4):methanol (85:15, v/v)deliveredat aﬂowrateof0.2 mL/minat 20 °C,
as described previously [21,22]. The ﬁrst set of experiments was
performed in the presence of 1 nM α-BTx (the AChR is mainly in the
restingstate; see [26]), andasecondsetof experimentswasdetermined in
parallel in the presence of 0.1 µM (±)-epibatidine (the AChR is mainly in
the desensitized state).
In the non-linear chromatography approach, concentration-de-
pendent asymmetric chromatographic traces are observed due to
slow adsorption/desorption rates. The mathematical approach used
in this study to resolve these non-linear conditions was the Impulse
Input Solution [31]. The chromatographic data were analyzed using
PeakFit v4.12 for Windows Software (SPSS Inc., Chicago, IL, USA)
following a previously reported protocol [21,32]. The details of this
approach and its application to the determination of the binding
kinetics of NCAs to neuronal AChRs were presented earlier [21,32,33].
Brieﬂy, the resultant peaks were ﬁtted to the Impulse Input Solution
model by adjusting four variables, namely a0–a3. The a2 variable was
directly used for the calculation of the dissociation rate constant (koff)
according to this equation:
koff = 1= a2t0ð Þ ð5Þ
where the dead time of the column, t0, is determined as the time
required for the elution of water. The a3 value was used to calculate
the association constant (Ka) for the formation of the ligand-receptor
complex in equilibrium using this relationship:
Ka = a3 = 18MC½  ð6Þ
where [18-MC] is the concentration of 18-MC. Both Ka and koff values
can be used to further calculate the association rate constant, kon
(kon=Ka ∙koff).
2.8. Thermodynamic parameters for the interaction of 18-MC with
Torpedo AChRs
The chromatographic elution of 18-MC from the CMAC-Torpedo
AChR column was carried out as explained in Section 2.7 at the
following temperatures: 10, 12, 16, 20, and 25 °C. For the tempera-
ture-dependence studies, van't Hoff plots were constructed according
to the following linear regression equation (reviewed in [1]):
lnKa = ΔS-= Rð Þ− ΔH- = Rð Þ 1= Tð Þ; ð7Þ
where the Ka valueswere obtained using Eq. (6), andΔS° andΔH° are the
standard entropy change and standard enthalpy change, respectively.
These parameterswere calculated using the slope (ΔH°=−Slope ∙R) and
y-intersect (ΔS°=y-intersect ∙R) values from the plots. In addition, the
entropic contribution was calculated as −TΔS°, and the free energy
change at 293K (ΔG20) was calculated using the Gibbs–Helmholtz
equation (reviewed in [1]):
ΔG20 = ΔH-−TΔS-: ð8Þ
The koff values obtained using Eq. (5) were also used to construct
the Arrhenius plots to determine the energy of activation (Ea) of thedissociation process, according to the Arrhenius equation (reviewed
in [1]):
ln koff = lnA− Ea = Rð Þ 1 = Tð Þ; ð9Þ
where A is the Arrhenius or pre-exponential factor, and Ea was
determined from the slope of the plot (Ea=−Slope ∙R). In turn, the Ea
values were used to calculate the enthalpy change of the transition
state (ΔH+) according to the following equation (reviewed in [1]):
ΔHþ = Ea−RT: ð10Þ
2.9. Molecular docking of 18-MC in muscle-type AChR ion channels
Amino acid sequences in the M2 transmembrane segments of the
AChR ion channel are highly conserved between different species and
subunits. However, the absolute numbering of amino acid residues
varies greatly between subunits, thus, the residues in M2 of AChR
subunits are referred to here using the prime nomenclature (1′ to 20′)
corresponding to residues Met243 to Glu262 in the Torpedo AChR α1-
subunit. As binding targets for modeling we ﬁrst used a structural
model of the pore region of AChR based on the cryo-electron
microscopy structure of the Torpedo AChR determined at ∼4 Å
resolution (PDB ID 2BG9) [34,35]. Subsequently, a model of the
human muscle AChR subtype was constructed applying homology/
comparative modeling methods on the Torpedo 2BG9 as a template.
Computational simulations were performed using the same
protocol as recently reported [17,22]. In the ﬁrst step, 18-MC
molecules in either the protonated or neutral form were sketched
using HyperChem 6.0 (HyperCube Inc., Gainesville, FL), optimized
using the semiempirical method AM1 (Polak–Ribiere algorithm to a
gradient lower than 0.1 kcal/Å/mol), and then transferred for the
subsequent step of ligand docking. The Molegro Virtual Docker (MVD
2008.2.4.0 Molegro ApS Aarhus, Denmark) was used for docking
simulations of ﬂexible ligands into the rigid target AChR model. The
docking space was limited and centered in the middle of the ion
channel and extended enough to ensure covering of the whole
channel domain for sampling simulations (docking space was deﬁned
as a sphere of 21 Å in diameter). The actual docking simulations were
performed using the following settings: numbers of runs=100;
maximal number of iterations=10,000; maximal number of
poses=10, and the pose representing the lowest value of the scoring
function (MolDockScore) for 18-MC was further analyzed.
3. Results
3.1. Inhibition of (±)-epibatidine-mediated Ca2+ inﬂux in TE671 cells by
18-MC, ibogaine, and phencyclidine
Since there is no previous information about the interaction of
ibogaine analogs with muscle AChRs, Ca2+ inﬂux experiments were
performed to compare the inhibitory potency of 18-MC with that
for ibogaine and PCP. First, the activation potency of (±)-
epibatidine was determined (EC50=0.26±0.04 µM; Fig. 1) by
following the ﬂuorescence increase in TE671-hα1β1γδ AChR cells
produced by (±)-epibatidine-induced Ca2+ inﬂux as described
previously [22,24]. To compare the inhibitory potency (IC50) of 18-
MC, ibogaine and PCP, TE671 cells were pre-incubated (5 min) with
each ligand and their inhibitory properties were assessed by (±)-
epibatidine-induced Ca2+ inﬂux experiments (Fig. 1A). The ob-
served values for ibogaine (17.0±3.0 µM) and PCP (31.0±2.0 µM)
(Table 1) were statistically identical to that obtained by 86Rb+
efﬂux experiments using the same human muscle AChR [7]. Our
results indicate that 18-MC (6.8±0.8 µM) is ∼2-fold more potent
than ibogaine, the archetypical member of this family of drugs,
Fig. 1. Effect of 18-methoxycoronaridine (18-MC), ibogaine, and PCP on (±)-
epibatidine-induced calcium inﬂux in TE671-hα1β1γδ cells. (A) Increased concentra-
tions of (±)-epibatidine (■) activate the hα1β1γδ AChR with potency EC50=0.26
±0.04 µM (nH=1.23±0.06). Subsequently, cells were pre-treated for 5 min with
several concentrations of 18-MC (○), ibogaine (□), and PCP (◊) followed by addition of
1 µM (±)-epibatidine. (B) Longer pre-treatment increases the inhibitory potency of 18-
MC on (±)-epibatidine-induced calcium inﬂux in TE671-hα1β1γδ cells. Pre-treatment
periods were: 5 min (○), 4 h (▼), and 24 h (♦), respectively. Responses in both plots
were normalized to the maximal (±)-epibatidine response which was set as 100%. The
calculated IC50 and nH values are summarized in Table 1. (C) Pre-treatment with 1 (♦),
10 (●), and 100 µM 18-MC (▲), respectively, inhibits (±)-epibatidine-induced calcium
inﬂux in TE671-hα1β1γδ cells in a dose dependent and noncompetitive manner. The
plots are representative of twenty-seven (■), nine (○), six (□), three (◊) and three
(▲,▼,♦,●) determinations, respectively, where the error bars represent the standard
deviation (S.D.) values.
Table 1
Inhibitory potency of 18-MC, ibogaine, and PCP on human muscle embryonic AChRs
obtained by Ca2+ inﬂux measurements.
NCA Pre-incubation time (min) IC50a (µM) nHb
18-MC 5 6.8±0.8 1.56±0.15
240 3.2±1.7 1.90±0.20
1440 2.8±1.1 1.61±0.13
Ibogaine 5 17.0±3.0 2.00±0.29
PCP 5 31.0±2.0 2.30±0.04
a Required drug concentration to produce 50% inhibition of agonist-activated AChR
ion channel ﬂux, obtained from Fig. 1.
b Hill coefﬁcient.
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indicate that 18-MC inhibits the hα1β1γδ AChR in a dose
dependent and noncompetitive manner (Fig. 1C). Interestingly,
longer pre-incubation periods increase the potency of 18-MC
by ∼2-fold (Fig. 1B; Table 1). The same effect was observed either
at 4 or 24 h pre-incubation. An obvious explanation is that the AChR
is desensitized in the prolonged presence of 18-MC, and thus, the
afﬁnity and potency of 18-MC is increased. However, we cannot rule
out other pleiotropic mechanisms such as modulation of AChR
phosphorylation.3.2. Equilibrium binding of [3H]18-MC to the Torpedo AChR
In a ﬁrst attempt to study the interaction of 18-MC with the
muscle-type AChR ion channel, the afﬁnity of [3H]18-MC binding to
Torpedo AChRmembranes was determined. Fig. 2A shows the total (in
the absence of 18-MC), nonspeciﬁc (in the presence of 100 µM 18-
MC), and speciﬁc (total−nonspeciﬁc) [3H]18-MC binding to Torpedo
AChR membranes in the desensitized/CCh-bound state. Fig. 2B shows
the Rosenthal–Scatchard plot for this speciﬁc binding. The results
indicate that the Torpedo AChR ion channel has a single [3H]18-MC
binding site (stoichiometric ratio=0.86±0.13 binding sites/AChR)
of relatively high afﬁnity (Kd=0.23±0.04 µM).Fig. 2. Equilibrium binding of [3H]18-MC to Torpedo AChRs in the desensitized/CCh-
bound state. (A) Total (□), nonspeciﬁc (●) (in the presence of 100 µM 18-MC), and
speciﬁc (○) (total−nonspeciﬁc binding) [3H]18-MC binding. Torpedo AChR native
membranes (0.5 µM) were suspended in BS buffer, in the presence of 1 mM CCh, and
pre-incubated for 30 min at RT. Then, the total volume of the membrane suspensions
(total and nonspeciﬁc binding) was divided into aliquots and increasing concentrations
of [3H]18-MC+18-MC (i.e., 0.07 to 1.2 µM) were added to each tube and incubated for
2 h at RT. Finally, the AChR-bound [3H]18-MC was separated from the free ligand by
using the ﬁltration assay described in Section 2.4. (B) Rosenthal–Scatchard plot for [3H]
18-MC speciﬁc binding to the Torpedo AChR ion channel. The Kd value (0.23±0.04 µM)
was determined from the negative reciprocal of the slope, according to Eq. (1). The
stoichiometric ratio (0.86±0.13 binding sites/AChR) was obtained from the x-intersect
(when y=0) of the plot [B]/[F] versus [B] according to Eq. (1), considering the AChR
concentration in the assay. Shown is the combination of two separate experiments.
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Since the PCP/TCP binding sites have been previously character-
ized in muscle-type AChRs [14–19], we wanted to determine the
location of the 18-MC binding site relative to this domain. To this end,
we ﬁrst determined the inﬂuence of 18-MC (Fig. 3A), ibogaine
(Fig. 3A), and PCP (Fig. 3C) on [3H]18-MC binding to Torpedo AChRs in
the resting/α-bungarotoxin (α-BTx)-bound and desensitized/CCh-
bound states. And, vice versa, the effect of 18-MC on [3H]TCP (Fig. 4A)
and [3H]ibogaine (Fig. 4B) binding to the Torpedo AChR was also
determined. 18-MC inhibits ∼100% the speciﬁc binding of [3H]TCP
(Fig. 3A) and of [3H]ibogaine (Fig. 3B), and PCP inhibits ∼100% the
speciﬁc binding of [3H]18-MC (Fig. 3C) in both conformational states.
Comparing the Ki values in different conformational states (Table 2),
we can indicate that 18-MC binds to the [3H]TCP binding site with ∼8-Fig. 3. (A) Inhibition of [3H]18-MC binding to Torpedo AChRs in different conforma-
tional states by (A) 18-MC, (B) ibogaine, and (C) PCP, respectively. AChR-rich
membranes (0.3 µM) were equilibrated (2 h) with 3.6 (●) or 5.5 nM (○) [3H]18-MC,
in the presence of 1 mM CCh (●) (desensitized/CCh-bound state) or 1 µM α-BTx (○)
(resting/α-BTx-bound state), respectively, and increasing concentrations of the NCA
under study. Nonspeciﬁc binding was determined in the presence of 50 (●) or 100 µM
18-MC (○), respectively. Each plot is the combination of two separated experiments
each one performed in triplicate, where the error bars represent the standard deviation
(S.D.) values. From these plots the IC50 and nH values were obtained by nonlinear least-
squares ﬁt according to Eq. (2). Subsequently, the Ki values were calculated using
Eq. (3). The calculated Ki and nH values are summarized in Table 2.fold higher afﬁnity in the desensitized AChR than that in the resting
AChR. These experiments are in agreement with the [3H]18-MC
competition results indicating that 18-MC binds to the desensitized
AChR with ∼2-fold higher afﬁnity compared to that for the resting
AChR (Table 2). The Ki value for 18-MC obtained by [3H]ibogaine
competition experiments is in the same concentration range as that
obtained by [3H]TCP and [3H]18-MC competition experiments,
respectively (Table 2). The results from the [3H]18-MC competition
experiments indicate that ibogaine binds to this locus with similar
afﬁnity for the resting and desensitized AChRs (Table 2).
The results from the complementary experiments indicate that
PCP binds to the [3H]18-MC site with practically the same afﬁnity
(Ki=0.41±0.03 µM in the desensitized state, and 0.73±0.05 µM in
the resting state; see Table 2) as previously observed by [3H]TCP
equilibrium binding experiments in the desensitized (0.25±0.05 µM;
[28]) and resting (0.83±0.05 µM; [15]) AChRs, respectively.
The fact that the calculated nH values for 18-MC, ibogaine, and PCP
are close to unity (Table 2) indicates that 18-MC inhibits [3H]18-MC,
[3H]TCP and [3H]ibogaine binding, and that PCP inhibits [3H]18-MC
binding, in a non-cooperative manner. These data suggest that
ibogaine analogs and PCP interact with a single binding site, and
that these drugs probably inhibit radioligand binding in a steric
fashion.
3.4. Schild-type plots for 18-MC-induced inhibition of [3H]TCP binding
Although the previous competition binding results suggest that
18-MC inhibits [3H]TCP (Fig. 4A) binding to the desensitized Torpedo
AChR in a steric fashion, we cannot rule out that this competition is
produced by a potent allosteric mechanism as well. In this regard, we
determined whether 18-MC inhibits [3H]TCP binding to the desensi-
tized AChR in a steric or allosteric manner by Schild-type analyses
[30]. Fig. 5A shows the 18-MC-induced inhibition of [3H]TCP binding
at different initial concentrations of unlabeled PCP (i.e., 0, 3.1, 6.3, and
9.4 µM). At increased initial PCP concentrations, the plots were shifted
to the right, indicating that higher 18-MC amounts are required to
inhibit the binding of [3H]TCP at increased PCP concentrations (see
Fig. 5A). By means of a modiﬁed Schild-type plot (Fig. 5B) (see [14]),
we found a linear relationship between the initial concentration of
PCP and the extent of radioligand inhibition with a goodness of ﬁt
value (r2) of 0.92 (Fig. 4B). Based on Schild-type analyses [30], a linear
relationship (r2N0.6) suggests that 18-MC inhibits [3H]TCP binding to
the desensitized/CCh-bound AChR by a steric mechanism. A r2 value
lower than 0.6 would indicate that there is no linear relationship and
thus, that the inhibition is mediated by an allosteric mechanism.
Based on the steric mechanism of inhibition elicited by 18-MC, we
may infer that the 18-MC locus overlaps the PCP binding site within
the Torpedo AChR ion channel in the desensitized state.
3.5. Ibogaine analog-induced enhancement of [3H]cytisine binding to
Torpedo AChRs
In order to determine the mechanisms of inhibition elicited by
ibogaine analogs (e.g., receptor desensitization), we studied the effect
of 18-MC and ibogaine on the binding of the agonist [3H]cytisine to
AChRs in the resting but activatable state. Fig. 6 shows that both
ibogaine analogs enhance [3H]cytisine binding to Torpedo AChRs in
the resting but activatable state. A potential explanation for this
pharmacological effect is based on the fact that cytisine binds with
different afﬁnity to the resting and desensitized AChRs [24], and that
the AChRmembrane suspension contains an excess of agonist binding
sites (0.6 µM) compared with the initial concentration of [3H]cytisine
(7.7 nM). Since the cytisine Ki in the resting state is 1.6 µM [24], only a
small fraction of AChRs will be initially labeled with [3H]cytisine.
Using Eq. (2), and considering nH=1, a fractional occupancy (θ)
of ∼0.005% for [3H]cytisine bound to the resting AChR was calculated.
Table 2
Binding afﬁnity of 18-MC, ibogaine, and PCP for the Torpedo AChR in different conformational states.
Radioligand NCA Desensitized/CCh-bound state Resting/α-BTx-bound state
Ki
a (µM) nHb ΔGc (kJ mol−1) Kia (µM) nHb ΔGc (kJ mol−1)
[3H]TCP 18-MC 0.17±0.01 1.11±0.07 −38.6±0.1 1.4±0.1 0.89±0.06 −33.4±0.2
[3H]Ibogaine 18-MC 0.61±0.08 1.02±0.13 −35.5±0.3 ND ND ND
[3H]18-MC 18-MC 0.47±0.03 1.02±0.06 −36.1±0.2 1.0±0.1 0.70±0.05 −34.3±0.3
Ibogaine 9.3±0.6 1.11±0.07 −28.7±0.2 11±1 1.04±0.08 −28.3±0.2
PCP 0.41±0.03 0.76±0.03 −36.4±0.1 0.73±0.05 0.88±0.05 −35.0±0.2
ND, not determined.
a Values were calculated from Fig. 3A–C ([3H]18-MC competition experiments), Fig. 4A ([3H]TCP competition experiments), and Fig. 4B ([3H]ibogaine competition experiments),
respectively, using Eq. (3).
b Hill coefﬁcient.
c Values were calculated using Eq. (4), at the experimental temperature (298K).
1159H.R. Arias et al. / Biochimica et Biophysica Acta 1798 (2010) 1153–1163Thus, if the AChR is shifted to its high afﬁnity state (i.e., the
desensitized state), an increase in the fraction of AChR-bound [3H]
cytisine molecules can be expected. In this regard, using Eq. (2), and
considering that the cytisine Ki in the desensitized state is 0.45 µM
[24], a fractional occupancy of ∼0.017% for [3H]cytisine bound to the
desensitized AChR was obtained. This is an increase of ∼3-fold in
fractional occupancy. Coincident with this calculation, our binding
results indicate an increase of ∼2–2.5 times (see Fig. 6). The
explanation of our results is that when the ibogaine analog binds to
the ion channel, the AChR becomes desensitized thus, the afﬁnity of
[3H]cytisine is increased and subsequently, a larger fraction of AChR-
bound [3H]cytisine is observed. In order to quantify this enhanced
binding, the drug concentration to produce 50% increase of [3H]
cytisine bindingwas calculated. The apparent EC50s values are 28±10
and 0.3±0.1 µM for ibogaine and 18-MC, respectively. These data
indicate that ibogaine analogs enhance [3H]cytisine binding probablyFig. 4. 18-MC-induced inhibition of (A) [3H]TCP and (B) [3H]ibogaine binding to
Torpedo AChRs in different conformational states. AChR-richmembranes (0.3 µM) were
equilibrated (2 h) with 4 nM [3H]TCP in the presence of 1 mM CCh (□) (desensitized/
CCh-bound state) or 1 µM α-BTx (■) (resting/α-BTx-bound state), or alternatively
with 19 nM [3H]ibogaine in the presence of 1 mM CCh (□), and increasing
concentrations of 18-MC. Nonspeciﬁc binding was determined in the presence of
100 µM PCP. Each plot is the combination of two separated experiments each one
performed in triplicate, where the error bars represent the standard deviation (S.D.)
values. From these plots the IC50 and nH values were obtained by nonlinear least-
squares ﬁt according to Eq. (2). Subsequently, the Ki values were calculated using
Eq. (3). The calculated Ki and nH values are summarized in Table 2.by inducing AChR desensitization, and that 18-MC is ∼90-fold more
potent than ibogaine to induce AChR desensitization.
3.6. Binding kinetics of 18-MC determined by non-linear chromatography
Non-linear chromatography results permitted us to determine the
koff and Ka values according to Eqs. (5) and (6), respectively, and thus, to
further calculate the kon value for 18-MCwhen they bind to the Torpedo
AChR in different conformational states (see Table 3). The results
indicate that the dissociation rate constant (koff) of 18-MC was slightly
slower (0.077±0.001 s−1) when the column was exposed to (±)-
epibatidine (the AChR is mainly in the desensitized state) compared to
that exposed toα-BTx (the AChR ismainly in the resting state; see [26])
(0.109±0.005 s−1). This result indicates that 18-MC is dissociated fromFig. 5. Schild-plot for 18-MC-induced inhibition of [3H]TCP binding to the Torpedo AChR
in the desensitized/CCh-bound state. (A) AChR-rich membranes (0.3 µM nAChR) were
equilibrated with [3H]TCP, in the presence of 1 mM CCh (desensitized state), at initial
PCP concentrations of 0 (control;■), 3.1 (△), 6.3 (□), and 9.4 µM (○), respectively. The
apparent IC50 values were calculated by nonlinear least-squares ﬁt according to Eq. (2).
Shown is the average of experiments performed in triplicate. (B) Modiﬁed Schild-plot
for 18-MC-induced inhibition of [3H]TCP binding. The plot shows a linear relationship
with a r2 value of 0.92. Shown is the result of experiments performed in triplicate,
where the error bars represent the standard deviation (S.D.) values.
Fig. 6. Ibogaine analog-induced enhancement of [3H]cytisine binding to Torpedo AChRs
in the resting but activatable state. AChR native membranes (0.3 µM nAChR) were
equilibrated (30 min) with 7.7 nM [3H]cytisine, and increasing concentrations of
ibogaine (●) and 18-MC (○), respectively. Each plot is the combination of 2–3
separated experiments each one performed in triplicate, where the error bars represent
the standard deviation (S.D.) values. The apparent EC50 values, obtained according to
Eq. (2), were 28±10 (apparent nH=0.99±0.22) and 0.3±0.1 μM (apparent
nH=0.81±0.20) for ibogaine and 18-MC, respectively.
Table 4
Thermodynamic parameters of 18-MC binding to Torpedo AChRs in different







ΔH° (kJ mol−1)c −18.5±1.1 −25.0±1.1
−TΔS° (kJ mol−1)d −15.5±1.1 −11.2±1.2
ΔG20 (kJ mol−1)e −34.0±1.4 −36.3±1.4
Ea (kJ mol−1)f 16.4±0.7 22.4±1.5
ΔH+ (kJ mol−1)g 13.9±0.7 20.0±1.5
The CMAC-Torpedo AChR column elution was performed in the presence of either α-
BTxa (the AChR is mainly in the resting state) or (±)-epibatidineb (the AChR is mainly
in the desensitized state).
c,dThe thermodynamic parameters ΔH° and ΔS° were calculated from Fig. 1A (see
Supplementary data) according to Eq. (7).
eValues were calculated using Eq. (8).
fValues for the process of drug dissociation were obtained from Fig. 1B (see
Supplementary data) according to Eq. (9).
gValues were calculated using Eq. (10).
1160 H.R. Arias et al. / Biochimica et Biophysica Acta 1798 (2010) 1153–1163the desensitized Torpedo AChR ion channel at a slower rate than that
from the resting AChR ion channel. This explains the pharmacological
mechanism by which 18-MC binds to its own site with ∼2-fold higher
afﬁnity to the desensitized AChR compared to the resting AChR (see
Table 2).
3.7. Thermodynamic parameters for the interaction of 18-MC with the
Torpedo AChR
In previous studies, an increase in the temperature changed the
chromatographic retention of several NCAs including dextromethor-
phan and levomethorphan [36], and bupropion [22]. Thus, the
temperature-dependent results can then be analyzed using the van't
Hoff plot (see Eq. (7)) to calculate the changes in enthalpy (ΔH°) and
entropy (ΔS°) associated with the interactions of 18-MC with the
immobilized AChR. In this study, increasing temperatures produced
signiﬁcant changes in the retention of 18-MC on the CMAC-Torpedo
AChR column in the presence of either α-BTx (resting state; see [26])
or (±)-epibatidine (desensitized state), respectively. Since the
resulting van't Hoff plots were linear (Fig. S1A in the Supplementary
data), the thermodynamic parameters ΔH° and ΔS° were calculated
from the slopes and intercepts of the van't Hoff plots, respectively,
according to Eq. (7), whereas ΔG20 was calculated according to Eq. (8)
(Table 4). The linearity of the van't Hoff plots indicates an invariant
retention mechanism over the temperature range studied [36,37].
The thermodynamic results indicate that the ΔH° and −TΔS°
values obtained for 18-MC in the resting AChR are practically in the
same energetic range, whereas the enthalpic contribution is more
than 2-fold higher than the entropic contribution in the desensitized
AChR (Table 4). This indicates that the enthalpic contribution is moreTable 3
Kinetic and thermodynamic parameters of 18-MC binding to Torpedo AChRs in different
conformational states determined by non-linear chromatography studies.
Parameter α-BTx treated columna Epibatidine treated columnb
koff (s−1)c 0.109±0.005 0.077±0.001
kon (s−1 µM−1) 0.123±0.002 0.228±0.003
Ka (µM−1)d 1.13±0.04 2.97±0.01
ΔG20 (kJ mol−1)e −33.9±0.1 −36.3±0.1
The CMAC-Torpedo AChR column was pre-treated with either α-BTxa (the AChR is
mainly in the resting state) or (±)-epibatidineb (the AChR is mainly in the desensitized
state).
c,dConstants were empirically determined using Eqs. (5) and (6), respectively, whereas
the kon values were calculated as kon=koff ⋅ Ka.
eValues were calculated using Eq. (4).important in the desensitized state compared to that in the resting
state. Since negative ΔH° values suggest the existence of attractive
forces (e.g., van der Waals, hydrogen bond, and electrostatic
interactions) (reviewed in [1]), the interactions between 18-MC and
the ion channel are stronger when the AChR becomes desensitized,
increasing the stability of the molecule within the ion channel in this
particular state. This is in agreement with higher ΔG values for the
desensitized AChR compared with that for the resting AChR obtained
by radioligand binding assays (Table 2). On the other hand, the local
conformational changes or solvent reorganization in the binding
pocket of the resting AChR elicited by 18-MC ismore pronounced than
that in the desensitized AChR binding site.
Since only small changes in the kinetic parameters for 18-MC
between the resting/α-BTx-bound and desensitized/epibatidine-
bound states at 20 °C were observed (see Table 3), additional studies
were conducted in the 10–25 °C temperature range. In this regard,
Arrhenius plots were constructed using the determined koff values
(see Eq. (5)) for 18-MC at different temperatures (Fig. S1B in the
Supplementary data). Since the Arrhenius plots are different from
zero, the drug dissociation process is mediatedmainly by an enthalpic
component. To quantify this component, the Ea value was ﬁrst
calculated from the Arrhenius plots (see Eq. (9)), and the ΔH+ value
was subsequently calculated using Eq. (10) (Table 4). The fact that the
Ea value in the desensitized state is higher than that in the resting
state indicates that the energy barrier for drug dissociation from the
desensitized ion channel is higher than that from the resting ion
channel. This correlates well with a higher ΔH+ value in the
desensitized state compared to that in the resting state.
3.8. Molecular docking of 18-MC in Torpedo and human muscle AChR
ion channels
18-MC in the neutral and protonated states was docked to models
of human muscle (Fig. 7A) and Torpedo (Fig. 7B) ion channels,
respectively. Molegro Virtual Docker generated a series of docking
poses and ranked them using energy-based criterion using the
embedded scoring function MolDockScore. Based on this ranking,
the lowest energy pose of the AChR–ligand complexes was selected
and shown in Fig. 7. In both models, the docked 18-MC molecule
interacted exclusively with the M2 helices provided by each subunit,
and no interactions with other transmembrane helices were ob-
served. More speciﬁcally, 18-MC interacted with the luminal domain
formed between the serine (position 6′) and valine (position 13′)
rings. However, M2 helices are quite dissimilar when amino acid
sequences of respective AChR subunits from Torpedo and humans are
considered, especially in residues from the rings exposed to the center
of the channel. For instance, in the serine ring (position 6′), both β1-
Fig. 7. Complexes formed between 18-MC and AChR ion channel models obtained by
molecular docking. (A) Side view of the lowest energy complex formed between
neutral 18-MC and the human muscle AChR ion channel. Receptor subunits are shown
in the secondary structure mode (M2 helices, yellow; other transmembrane helices,
blue) with residues forming the serine (SER) (position 6′), leucine (LEU) (positions 9′),
and valine (VAL) (position 13′) rings, shown explicitly in stick mode. Green arrows
indicate hydrogen bonds formed between the pyrrole amino group and the α1-Ser252
residue (position 10′), another between the ligand ionizable amino group and γ-
Asn257 at the SER ring, and a third one between the carbonyl of the ester group and β1-
Thr263 (position 10′). A similar interaction was obtained for protonated 18-MC. (B)
Side view of the lowest energy complex formed between protonated 18-MC and the
Torpedo AChR ion channel. The subunit γ was hidden for clarity, and the order of the
remaining subunits is (from the left):α1, β1, δ,α1. The ether and ester groups from 18-
MC form hydrogen bonds with two Ser residues, each one from the respective α1 and
β1 subunits, forming the SER ring. Another strong hydrogen bond interaction is
observed between the charged amino group and the same α1-Ser residue. 18-MC
interacts with the LEU and VAL rings by additional weaker van der Waals contacts. A
similar interaction was obtained for neutral 18-MC.
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the respective Phe and Asn residues in the human muscle subtype,
whereas the Torpedo δ-Cys247 is exchanged into Ser in the human
model. Docking results indicate that the binding orientation of the 18-
MC molecule in the complex differs depending on the model used
(Torpedo versus human).
In the case of the interaction between neutral 18-MC and the
human muscle AChR ion channel model (Fig. 7A), three hydrogen
bonds interacting with 18-MC can be found: one between the pyrrole
amino group and the α1-Ser252 residue (position 10′), another
between the ligand ionizable amino group and γ-Asn257 (position 6′),
and a third one between the carbonyl of the ester group andβ1-Thr263
(position 10′). The latter two residues are not present at these
positions in the Torpedo AChR ion channel model, and this difference
seems to be responsible for the observed complex divergences. Asimilar orientation for the protonated version of 18-MC was observed
in docking to the human muscle AChR model.
A different position with optimized interactions is found for
neutral 18-MC docked in the Torpedo AChR ion channel (Fig. 7B)
compared to that for the human muscle AChR ion channel (Fig. 7A).
The calculated docking energy (MolDockScore values) for the human
muscle AChR (−119.6 and −116.1 kJ/mol for the neutral and
protonated form, respectively) is very similar as that for the Torpedo
AChR (−113.8 and −110.4 kJ/mol for the neutral and protonated
form, respectively). Although 18-MC interacts with each AChR
channel with practically the same binding energy, its luminal
orientation is different in both complexes. In the Torpedo AChR ion
channel, the ligand is oriented in amanner allowing its ether and ester
groups to form hydrogen bonds with two Ser residues, each one from
the respective α1 and β1 subunits, forming the serine ring (position
6′) (Fig. 7B). Another strong hydrogen bond interaction can be
observed between the charged amino group and the same α1-Ser
residue. In addition, 18-MC interacts with non-polar residues by weak
van der Waals contacts ranging from the leucine (position 9′) to
valine (position 13′) rings. Essentially the same mode of interaction
was observed for the protonated version of the molecule.
4. Discussion
Ibogaine analogs pharmacologically behave as NCAs of several
AChRs [6–10]. However, we do not have a complete understanding of
how these drugs interact with the AChR ion channel in different
conformational states. In this regard, this study is an attempt to
characterize the interactions of 18-MC with the archetype of the Cys-
loop ligand-gated ion channels superfamily, the muscle-type AChR, in
distinct conformational states, and to compare themwith that for PCP,
a well known NCA. To this end, radioligand binding assays, Ca2+
inﬂux, kinetic and thermodynamic measurements, and molecular
modeling and docking studies were performed. Although this study
does not directly address the anti-addictive properties of ibogaine
analogs, the results of this work should ultimately provide a better
understanding of how these compounds interact with the AChR, and
will bestow the basic knowledge to afford the study of the interaction
of these compounds with neuronal-type AChRs, more suitable targets
for the anti-addictive action of these compounds.
4.1. 18-MC interaction with the agonist-activated AChR ion channel
The effect of 18-MC on (±)-epibatidine-activated Ca2+ inﬂux in
TE671 cells was compared to that for ibogaine and PCP using a pre-
incubation protocol (Fig. 1A). Ibogaine and PCP showed inhibitory
potencies similar to that determined previously by 86Rb+ efﬂux
experiments using the same cell type [7], but they were ∼2- and ∼4-
fold less potent than 18-MC (see Table 1). Interestingly, the opposite
ratio was observed in the α3β4 AChR, where 18-MC and ibogaine
inhibit this receptor type with IC50 values of 0.75–0.90 and 0.22 µM,
respectively [8,9]. This is the ﬁrst time where the interaction of 18-MC
with muscle AChRs is demonstrated, supporting the view that
ibogaine analogs inhibit AChRs in a noncompetitive manner (see
Fig. 1C). Based on our own results and on the inhibitory potency of 18-
MC for other AChR types [8,9], the following AChR speciﬁcity
sequence was obtained: α3β4 (0.75–0.90 µM) Nα1β1γδ
(6.8 µM)Nα4β2 (N20 µM).
The fact that the nH values for 18-MC, ibogaine, and PCP are higher
than unity (see Table 1) indicates that the inhibitory process is
produced in a cooperative manner, suggesting that there are
potentially more than one binding site for these NCAs in the activated
muscle AChR ion channel or that there are more than one mechanism
of inhibition. In this regard, our [3H]cytisine results indicate that
ibogaine analogs induce an enhancement of agonist binding to the
resting but activatable AChR (Fig. 6), suggesting that the analogs may
1162 H.R. Arias et al. / Biochimica et Biophysica Acta 1798 (2010) 1153–1163induce AChR desensitization. This is supported by the observed higher
potency of 18-MC when it is pre-incubated for long periods (4 and
24 h) (Table 1). Finally, there is a good correlation between the IC50
(Table 1) and apparent EC50 values, indicating that 18-MC is more
potent than ibogaine inhibiting Ca2+ inﬂux as well as enhancing [3H]
cytisine binding, respectively.
4.2. 18-MC interaction with the desensitized and resting AChR ion
channels
The results from the [3H]TCP competition binding experiments
indicate that 18-MC binds with ∼8-fold higher afﬁnity to the
desensitized/CCh-bound Torpedo AChR compared to the resting/α-
BTx-bound AChR (see Table 2). The calculated Ki value for 18-MC
(0.17±0.01 µM; see Table 2) obtained in the [3H]TCP competition
binding experiments when the AChR is in the desensitized/CCh-
bound state is practically the same as that determined by equilibrium
binding (Kd=0.23±0.04 µM; see Fig. 2). The observed higher afﬁnity
of 18-MC for the [3H]TCP locus in the desensitized AChR is
corroborated by the [3H]18-MC competition results (Table 2). The
observed higher afﬁnity of 18-MC for the desensitized AChR
corresponds very well with its high desensitizing potency. In this
regard, a potential mechanism can be envisioned where 18-MC ﬁrst
induces AChR desensitization and in this conformational state, the
drug is maintained for longer time in the bound state (i.e., see smaller
koff value in Table 3). Since this hypothetic scheme adds a new
dimension to the inhibitory mechanisms elicited by ibogaine analogs,
further experiments deserve to be performed to support this
possibility.
The radioligand competition experiments also indicate that 18-MC
inhibits the binding of [3H]TCP (the structural and functional analog of
PCP) and vice versa, that PCP inhibits the binding of [3H]18-MC to
desensitized/CCh-bound AChRs with nH values close to unity
(Table 2). This suggests that both drugs may be interacting with a
single binding site in the desensitized AChR. Although this evidence
suggests a steric mode of competition between 18-MC and PCP, we
cannot rule out the possibility of a strong allosteric effect as well. In
this regard, Schild-type analyses indicate that 18-MC displaces [3H]
TCP binding from its site in the desensitized/CCh-bound state AChR
by a steric mechanism (Fig. 5). These data suggest that the 18-MC
binding site overlaps the high afﬁnity PCP locus in the desensitized
AChR. This conclusion is supported by our molecular docking results.
The analysis of the obtained molecular complexes clearly indicates
that 18-MC in either the neutral or protonated form (see Fig. 7) binds
to the middle portion of both muscle AChR ion channels (human and
Torpedo) between the serine (position 6′) and valine (position 13′)
rings. Molecular docking results also demonstrate the existence of a
network of hydrogen bond interactions between different 18-MC
moieties and several residues located at the serine ring (position 6′)
and at position 10′, as well as additional van der Waals interactions
with the adjacent serine (position 6′), leucine (position 9′), and valine
(position 13′) rings (see Fig. 7B). In turn, these results are in
agreement with the postulated location of the PCP binding site in
the desensitized AChR ion channel. For instance, photoafﬁnity labeling
[18,38] and molecular docking [17] studies indicated that the PCP
locus is located between the threonine (position 2′) and leucine
(position 9′) rings. The same basic results were obtained for several
antidepressants in muscle AChR ion channels [17,22,24]. In conclu-
sion, our data agree with a model where overlapping binding sites
exist for ibogaine analogs, PCP, and antidepressants, in the desensi-
tized AChR ion channel.
The radioligand binding results using AChRs in the resting state
indicate that 18-MC interacts with the [3H]18-MC locus with
practically the same afﬁnity (1.0±0.1 μM) as that for the [3H]TCP
site (1.4±0.1 µM) (see Table 2). Considering that these competition
results present nH values close to unity, we suggest that there existoverlapping binding sites for ibogaine analogs and PCP. Interestingly,
the thermodynamic studies support the notion that the interaction of
18-MC with the resting AChR ion channel (i.e., mixed enthalpic–
entropic) is different to that with the desensitized AChR ion channel
(i.e., more enthalpic than entropic). This difference suggests that
attractive forces are more important than local conformational
changes or solvent reorganization in the 18-MC binding pocket of
the desensitized AChR compared to the resting AChR. Previous
thermodynamic studies indicated that bupropion [22] and PCP [39]
interact with the Torpedo AChR ion channel by entropy-driven
mechanisms. The contrasting result obtained in the desensitized
state suggests that 18-MC interacts with its binding site by
mechanisms different to that for bupropion and PCP.
Considering the above results, we envision a mechanistic process
where 18-MC ﬁrst binds to its site in the resting AChR ion channel
with relatively low afﬁnity. Subsequently, 18-MC blocks the
activated (open) channel and induces receptor desensitization
increasing its afﬁnity for the desensitized ion channel. In this
conformational state, 18-MC interacts with a binding domain located
between the serine and valine rings that is shared by antidepressants
and PCP. The formation of hydrogen bonds with the serine ring and
additional van der Waals contacts with the serine, leucine, and valine
rings, ﬁnally decreases the dissociation of 18-MC from the
desensitized ion channel. Our results also suggest that ibogaine
analogs can inhibit muscle AChRs by a combination of several
noncompetitive inhibitory mechanisms including, ion channel
blocking and AChR desensitization.Acknowledgements
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